keyword
MENU ▼
Read by QxMD icon Read
search

arthritis & rheumatology

keyword
https://www.readbyqxmd.com/read/29148421/a-validation-study-of-the-simple-psoriatic-arthritis-screening-sipas-questionnaire-to-screen-psoriasis-patients-for-psoriatic-arthritis
#1
Fausto Salaffi, Marco Di Carlo, Michele Maria Luchetti, Eleonora Di Donato, Anna Campanati, Devis Benfaremo, Massimiliano Nicolini, Marina Carotti, Alfredo Giacchetti, Giulia Ganzetti, Leonardo Bugatti, Armando Gabrielli, Anna Maria Offidani
OBJECTIVES: To validate in a multicentric cohort of patients a self-administered PsA screening tool, called Simple Psoriatic Arthritis Screening (SiPAS) questionnaire, to screen psoriasis patients for signs and symptoms of PsA. METHODS: The SiPAS questionnaire was validated in a multicentric Italian cohort of psoriasis patients referred to two rheumatological centres. RESULTS: A total of 202 psoriasis patients were screened with SiPAS in the validation study...
November 16, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29146737/rheumatic-disorders-associated-with-immune-checkpoint-inhibitors-in-patients-with-cancer-clinical-aspects-and-relationship-with-tumour-response-a-single-centre-prospective-cohort-study
#2
Marie Kostine, Léa Rouxel, Thomas Barnetche, Rémi Veillon, Florent Martin, Caroline Dutriaux, Léa Dousset, Anne Pham-Ledard, Sorilla Prey, Marie Beylot-Barry, Amaury Daste, Marine Gross-Goupil, Julie Lallier, Alain Ravaud, Edouard Forcade, Bernard Bannwarth, Marie-Elise Truchetet, Christophe Richez, Nadia Mehsen, Thierry Schaeverbeke
OBJECTIVES: To evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation with tumour response. METHODS: This was a single-centre prospective observational study including all cancer patients receiving ICIs. The occurrence of irAEs and tumour response was assessed on a regular basis. Patients who experienced musculoskeletal symptoms were referred to the department of rheumatology for clinical evaluation and management...
November 16, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29142041/occurrence-of-serious-infection-in-patients-with-rheumatoid-arthritis-treated-with-biologics-and-denosumab-observed-in-a-clinical-setting
#3
Arthur N Lau, Matthew Wong-Pack, Rod Rodjanapiches, George Ioannidis, Sally Wade, Leslie Spangler, Akhila Balasubramanian, Nicola Pannacciulli, Celia J F Lin, Patrick Roy-Gayos, William G Bensen, Robert Bensen, Jonathan D Adachi
OBJECTIVE: Previous studies combining biologic disease-modifying antirheumatic drugs (bDMARD) to treat rheumatoid arthritis (RA) have shown an increased risk of infection. However, the risk of infection with concurrent use of denosumab, a biologic agent for the treatment of osteoporosis, and a bDMARD remains unclear. Here, we evaluated the incidence of serious and opportunistic infections in patients treated concurrently with denosumab and a bDMARD and patients treated with a bDMARD alone...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29142040/use-of-disease-modifying-antirheumatic-drugs-for-inflammatory-arthritis-in-us-veterans-effect-of-specialty-care-and-geographic-distance
#4
Jessica A Walsh, Shaobo Pei, Zachary Burningham, Gopi Penmetsa, Grant W Cannon, Daniel O Clegg, Brian C Sauer
OBJECTIVE: To evaluate the effect of access to and distance from rheumatology care on the use of disease-modifying antirheumatic drugs (DMARD) in US veterans with inflammatory arthritis (IA). METHODS: Provider encounters and DMARD dispensations for IA (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) were evaluated in national Veterans Affairs (VA) datasets between January 1, 2015, and December 31, 2015. RESULTS: Among 12,589 veterans with IA, 23...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29142036/effect-of-glucocorticoids-on-the-clinical-and-radiographic-efficacy-of-tofacitinib-in-patients-with-rheumatoid-arthritis-a-posthoc-analysis-of-data-from-6-phase-iii-studies
#5
Christina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, Peter Nash, Cristiano A F Zerbini, Carol A Connell, Haiyun Fan, Kenneth Kwok, Eustratios Bananis, Roy Fleischmann
OBJECTIVE: Tofacitinib has been investigated for the treatment of rheumatoid arthritis (RA) in phase III studies in which concomitant glucocorticoids (GC) were allowed. We analyzed the effect of GC use on efficacy outcomes in patients with RA receiving tofacitinib and/or methotrexate (MTX) or conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in these studies. METHODS: Our posthoc analysis included data from 6 phase III studies (NCT01039688; NCT00814307; NCT00847613; NCT00853385; NCT00856544; NCT00960440)...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29142030/plasma-microrna-profiles-in-patients-with-early-rheumatoid-arthritis-responding-to-adalimumab-plus-methotrexate-vs-methotrexate-alone-a-placebo-controlled-clinical-trial
#6
Jacob Sode, Sophine B Krintel, Anting Liu Carlsen, Merete L Hetland, Julia S Johansen, Kim Hørslev-Petersen, Kristian Stengaard-Pedersen, Torkell Ellingsen, Mark Burton, Peter Junker, Mikkel Østergaard, Niels H H Heegaard
OBJECTIVE: The aim was to identify plasma (i.e., cell-free) microRNA (miRNA) predicting antitumor necrosis and/or methotrexate (MTX) treatment response in patients enrolled in an investigator-initiated, prospective, double-blinded, placebo-controlled trial (The OPERA study, NCT00660647). METHODS: We included 180 disease-modifying antirheumatic drug-naive patients with early rheumatoid arthritis (RA) randomized to adalimumab (ADA; n = 89) or placebo (n = 91) in combination with MTX...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29141677/factors-associated-with-oral-glucocorticoid-use-in-patients-with-rheumatoid-arthritis-a-drug-use-study-from-a-prospective-national-biologics-registry
#7
Rachel J Black, Susan Lester, Rachelle Buchbinder, Claire Barrett, Marissa Lassere, Lyn March, Samuel Whittle, Catherine L Hill
BACKGROUND: Glucocorticoids (GCs) are used in ~ 60% of patients with rheumatoid arthritis (RA). Although disease-modifying, they also have significant adverse effects. Understanding factors associated with GC use may help minimise exposure. The aims of the present study were to describe oral GC use in RA; determine any change in use over time; and determine factors associated with oral GC use, commencement or cessation. METHODS: Adult patients with RA were identified in the Australian Rheumatology Association Database (ARAD), a national Australian registry that collects long-term outcome data from patients with inflammatory arthritis...
November 15, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29141665/matrix-metalloproteinase-3-and-the-7-joint-ultrasound-score-in-the-assessment-of-disease-activity-and-therapeutic-efficacy-in-patients-with-moderate-to-severe-rheumatoid-arthritis
#8
Ling Zhou, Geng Wang, Xin Liu, Jing Song, Ling Chen, Huji Xu
BACKGROUND: This study aimed to investigate the reliability and validity of serum matrix metalloproteinase-3 (MMP-3) levels and articular ultrasound (US) scores in assessing disease activity and therapeutic response in rheumatoid arthritis (RA) patients. METHODS: A total of 151 RA patients were enrolled, of whom 22 were treated with certolizumab pegol (Cimzia, CZP). The RA patients were divided into the following four subgroups according to their disease activity score in 28 joints (DAS28): stable, mild activity, moderate activity, and high activity...
November 15, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29138986/secukinumab-in-active-rheumatoid-arthritis-after-anti-tnf%C3%AE-therapy-a-randomized-double-blind-placebo-controlled-phase-3-study
#9
Hasan Tahir, Atul Deodhar, Mark Genovese, Tsutomu Takeuchi, Jacob Aelion, Filip Van den Bosch, Sibylle Haemmerle, Hanno B Richards
INTRODUCTION: 'REASSURE' (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF-inhibitors). METHODS: A total of 637 patients were randomized (1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks (starting from week 8) or placebo at the same dosing schedule...
November 14, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29138257/clinical-juvenile-arthritis-disease-activity-score-proves-to-be-a-useful-tool-in-treat-to-target-therapy-in-juvenile-idiopathic-arthritis
#10
Joost F Swart, E H Pieter van Dijkhuizen, Nico M Wulffraat, Sytze de Roock
OBJECTIVES: To assess if the Juvenile Arthritis Disease Activity Score (JADAS71) could be used to correctly identify patients with juvenile idiopathic arthritis (JIA) in need of antitumour necrosis factor therapy (anti-TNF) therapy 3 and 6 months after start of methotrexate (MTX). METHODS: Monocentric retrospective cohort study from 2011 to 2015 analysing all patients with oligoarticular JIA (OJIA) (n=39) and polyarticular course JIA (PJIA) (n=74) first starting MTX...
November 14, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29134891/efficacy-and-safety-of-baricitinib-in-japanese-patients-with-rheumatoid-arthritis-subgroup-analyses-of-four-multinational-phase-3-randomized-trials
#11
Yoshiya Tanaka, Tatsuya Atsumi, Koichi Amano, Masayoshi Harigai, Taeko Ishii, Osamu Kawaguchi, Terence P Rooney, Naotsugu Akashi, Tsutomu Takeuchi
OBJECTIVES: To evaluate efficacy/safety of baricitinib for rheumatoid arthritis (RA) in Japanese subpopulations from four phase 3 studies, and assess whether results in these subpopulations are consistent with the overall study populations. METHODS: Subgroup analyses (394 patients) of four phase 3 randomized controlled trials: RA-BEGIN [no or limited treatment with disease-modifying antirheumatic drugs (DMARDs)], RA-BEAM [inadequate response (IR) to methotrexate], RA-BUILD [IR to conventional synthetic DMARDs (csDMARDs)], and RA-BEACON (IR to tumor necrosis factor inhibitors receiving csDMARDs)...
November 14, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29134239/temporomandibular-joint-atlas-for-detection-and-grading-of-juvenile-idiopathic-arthritis-involvement-by-magnetic-resonance-imaging
#12
Christian J Kellenberger, Thitiporn Junhasavasdikul, Mirkamal Tolend, Andrea S Doria
Contrast-enhanced magnetic resonance imaging (MRI) is considered the diagnostic standard for identifying involvement of the temporomandibular joint by juvenile idiopathic arthritis. Early or active arthritis is shown as bone marrow oedema, joint effusion, synovial thickening and increased joint enhancement. Subsequent joint damage includes characteristic deformity of the mandibular condyle, bone erosion, disk abnormalities and short mandibular ramus due to impaired growth. In this pictorial essay, we illustrate normal MRI findings and growth-related changes of the temporomandibular joint in children...
November 13, 2017: Pediatric Radiology
https://www.readbyqxmd.com/read/29131689/do-pedometers-with-or-without-education-on-exercise-increase-functional-walking-capacity-and-physical-activity-level-in-adolescents-with-juvenile-idiopathic-arthritis
#13
Jill Blitz, Sara M Stern, Katherine Marzan
To evaluate the impact of pedometer use on the physical activity (PA) and functional walking capacity (FWC) of adolescents with juvenile idiopathic arthritis (JIA) and lower extremity (LE) involvement. Twenty-seven adolescents, aged 11-19 years with JIA and LE involvement, participated in the three-phase pedometer study that introduced the use of a pedometer and an education seminar at 6 weeks. Measurements were taken at the baseline first visit and at weeks 6, 12, and 20. The primary outcome measure was the 6-minute walk test (6MWT)...
November 13, 2017: Physiotherapy Theory and Practice
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#14
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
November 10, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29124397/long-term-glucocorticoid-treatment-in-patients-with-polymyalgia-rheumatica-giant-cell-arteritis-or-both-diseases-results-from-a-national-rheumatology-database
#15
Katinka Albrecht, Dörte Huscher, Frank Buttgereit, Martin Aringer, Guido Hoese, Wolfgang Ochs, Katja Thiele, Angela Zink
The objective of this study was to evaluate glucocorticoid (GC) use in patients with polymyalgia rheumatica (PMR), giant cell arteritis (GCA) or both diseases (PMR + GCA) under rheumatological care. Data from patients with PMR (n = 1420), GCA (n = 177) or PMR + GCA (n = 261) from the National Database of the German Collaborative Arthritis Centers were analyzed regarding GCs and related comorbidities (osteoporosis, diabetes and cardiovascular disease), stratified by disease duration (DD). Longitudinal data were analyzed for all patients with a DD ≤ 2 years at database entry (n = 1397)...
November 9, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29121263/high-prevalence-of-diabetes-in-patients-with-rheumatoid-arthritis-results-from-a-questionnaire-survey-linked-to-claims-data
#16
Katinka Albrecht, Andres Luque Ramos, Falk Hoffmann, Imke Redeker, Angela Zink
Objectives: To investigate the prevalence of diabetes in patients with RA and the impact of diabetes on self-reported outcomes and health care. Methods: RA patients between the ages of 18 and 79 years were randomly selected from a nationwide statutory health insurance fund and were surveyed about rheumatological care and disease burden. Comorbid diabetes (E10-14) was analysed regarding age, sex, BMI and socioeconomic status. Disease burden, comorbidity and prescriptions were compared in RA patients with and without diabetes...
November 7, 2017: Rheumatology
https://www.readbyqxmd.com/read/29116543/remission-assessment-of-rheumatoid-arthritis-in-daily-practice-in-china-a-cross-sectional-observational-study
#17
Huaqun Zhu, Ru Li, Zhanyun Da, Liqi Bi, Xiangpei Li, Yang Li, Chongyang Liu, Fengxiao Zhang, Zhijun Li, Xiangyuan Liu, Zhiyi Zhang, Lingyun Sun, Youlian Wang, Wei Zhang, Quan Jiang, Jinwei Chen, Qingping Chen, Zhenbin Li, Lijun Wu, Wencheng Qi, Jianhua Xu, Xiangjun Cui, Xiaofei Wang, Long Li, Xiaomei Leng, Guochun Wang, Dongbao Zhao, Lindi Jiang, Dongyi He, Xiaomin Liu, Ling Li, Yongfei Fang, Cibo Huang, Huaxiang Wu, Shaoxian Hu, Qin Li, Hui Song, Weiguo Xiao, Lu Gong, Liaojia Zhang, Xiaofeng Li, Zhanguo Li, Yin Su
The objective of this study is to evaluate the remission rate and describe the current use of medication in a large cohort of rheumatoid arthritis (RA) patients under routine clinical care in China. RA patients were recruited from 40 large teaching hospitals nationwide in China. Data regarding RA disease activity, medication treatment, and adverse events were recorded using a standardized clinical data questionnaire. RA remission was evaluated by the 28 Joint Disease Activity Score DAS28-ESR Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria...
November 7, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29116441/validation-of-the-toronto-psoriatic-arthritis-screen-ii-topas-ii-questionnaire-in-a-turkish-population
#18
Mehmet Tuncay Duruöz, Canan Şanal Toprak, Fırat Ulutatar
OBJECTIVE: To evaluate the TOPAS II questionnaire validation in a Turkish population. METHODS: The Turkish translation of ToPAS II was sent to us by the developer authors of the original index. Subjects were recruited from dermatology, physical medicine and rehabilitation, and rheumatology outpatient clinics. All patients' demographic parameters and ToPAS II questionnaire results were recorded. After patients completed the questionnaire they were assessed by a rheumatologist according to a standard protocol which includes a complete history, detailed physical examination, laboratory tests and CASPAR criteria...
November 7, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29116003/protocols-on-classification-monitoring-and-therapy-in-children-s-rheumatology-pro-kind-results-of-the-working-group-polyarticular-juvenile-idiopathic-arthritis
#19
REVIEW
Gerd Horneff, Ariane Klein, Gerd Ganser, Michaela Sailer-Höck, Annette Günther, Ivan Foeldvari, Frank Weller-Heinemann
OBJECTIVE: Several effective pharmacologic treatment options for polyarticual juvenile idiopathic arthritis (JIA) have emerged but initial treatment is heterogeneous in Germany. Therefore, the German Society of Pediatric Rheumatolgy has established a commission to develop consensus "Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND)" to harmonize diagnostic and treatment approaches for new-onset JIA in Germany. METHODS: A set of definitions for in- and exclusion, diagnostic workup, parameters for the evaluation of disease activity criteria, therapeutic options, medication dosing, monitoring recommendations, targets, definitions of a therapy failure and four therapeutic algorithms developed by a working group were agreed by web based survey to which all members of the GKJR have been invited...
November 7, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/29114388/epistatic-interactions-between-mutations-of-taci-tnfrsf13b-and-tcf3-result-in-a-severe-primary-immunodeficiency-disorder-and-systemic-lupus-erythematosus
#20
Rohan Ameratunga, Wikke Koopmans, See-Tarn Woon, Euphemia Leung, Klaus Lehnert, Charlotte A Slade, Jessica C Tempany, Anselm Enders, Richard Steele, Peter Browett, Philip D Hodgkin, Vanessa L Bryant
Common variable immunodeficiency disorders (CVID) are a group of primary immunodeficiencies where monogenetic causes account for only a fraction of cases. On this evidence, CVID is potentially polygenic and epistatic although there are, as yet, no examples to support this hypothesis. We have identified a non-consanguineous family, who carry the C104R (c.310T>C) mutation of the Transmembrane Activator Calcium-modulator and cyclophilin ligand Interactor (TACI, TNFRSF13B) gene. Variants in TNFRSF13B/TACI are identified in up to 10% of CVID patients, and are associated with, but not solely causative of CVID...
October 2017: Clinical & Translational Immunology
keyword
keyword
89631
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"